Lipoprotein(a) [Lp(a)], anti-Human

Catalogue Number: 400-45
Description
Product Name anti-Human Lipoprotein(a)
Source Polyclonal Antibody
Catalogue Number 400-45
Purity Affinity Purified
Form Liquid
Host Sheep
Concentration 0.5 - 2.0 mg/mL (A280nm)
Isotype IgG
Immunogen High purity human Lp(a)
Reactivity Human Lp(a), no cross-reactivity to ApoB.
Conjugate Unconjugated
Formulation Solution in sodium phosphate, sodium chloride, EDTA and 0.02% sodium azide, pH 7.2.
Pairing Information Antigen: 400-42 - Lipoprotein(a) antigen from human plasma
Antibody: 400-45 - anti-Human Lp(a) polyclonal antibody
Storage -20°C
Recertification 1 year
Synonyms Lp(a), LPA, AK38, APOA, LP
Overview

Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.

Introduction

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for developing vascular disease. Lp(a) is structurally similar to LDL but contains Apolipoprotein(a) (Apo(a)) in addition to Apolipoprotein B-100 (ApoB-100)1. Initially synthesized in the liver, Lp(a) circulates in the bloodstream to transport cholesterol and fats to other organs. Lp(a) can promote inflammation, foam cell formation, and thrombosis 2. Several studies have shown positive associations between elevated Lp(a) levels and increased risk of coronary heart disease/cardiovascular disease. Genetics have the most impact in an individual’s concentrations of Lp(a) and thus play a significant role in risk for premature development of coronary heart disease/cardiovascular disease 3,4.

Diagnostic Relevance

Normal levels of Lp(a) in the blood are less than 30 mg/dL; however, over 20% of adults in the United States have Lp(a) levels of >50 mg/dL3. Elevated levels of Lp(a) are associated with increased risk of coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke.

Identification

1.Synonyms: Lp(a), LPA, AK38, APOA, LP

2.Accession #:

a.P08519 (Apo(a))

b.P04114 (ApoB-100)

3.Gene:

a.Apo(a) gene [LPA] located on chromosome 6q26-27.

b.ApoB-100 gene [APOB] located on chromosome 2p24.

Properties

1.Structure: One molecule of ApoB-100 wrapped around a core of cholesteryl ester, triglyceride, phospholipids, and unesterified cholesterol. Apo(a) is covalently bound to the ApoB-100 through a disulfide bridge 5, 6.

2.Composition: 65% lipid, 27% protein, 8% carbohydrate.

3.Post-Translational Modification:

a.Apo(a): Autocatalytic cleavage, formation of disulfide bond, glycosylation

b.ApoB-100: Acetylation, formation of disulfide bond, glycosylation, lipidation, palmitoylated

4.Extinction Coefficient:

a.ApoB-100: E0.1%280nm = 0.79

5.Function:

a.Apo(a) is the main constituent of Lp(a). It has serine protease activity and is capable of autoproteolysis. Inhibits tissue-type plasminogen activator. (E.C. 3.4.21.-)

b.ApoB-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the ApoB/E receptor.

6.Molecular Weight:

a.Lipoprotein(a): approximately 1,000,000

b.Apo(a): approximately 250,000 to 800,000

c.ApoB-100: approximately 515,000

7.Stability: Stable as liquid at 2 – 8 °C. Recertification required one year after DOM. Avoid repeated freeze thaws.

8.Density: 1.05 – 1.12 g/mL 7.

References

1.Utermann, G. (1989) The mysteries of lipoprotein(a). Science 246, 904-910.

2.Erqou, S., Kaptoge, S., Perry, P. L., Di Angelantonio, E., Thompson, A., White, I. R., Marcovina, S. M., Collins, R., Thompson, S. G., and Danesh, J. (2012) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. The Journal of the American Medical Association (JAMA). 302, 412-423.

3.Nordestgaard, B. G., Chapman, M. J., Ray, K., Boren, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M. R., Tokgozoglu, L., and Tybjærg-Hansen, A. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 31, 2844-2853.

4.Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., Jackson, S., Di, M., Peach, M., Somaratne, R., Wasserman, S. M., Scott, R., and Stein, E. A. (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 57, 1086-1096.

5.Marconiva, S. M. and Albers, J. J. (2016) Lipoprotein (a) measurements for clinical application. Journal of Lipid Research. 57, 526-537.

6.Gaubatz, J. W., Heideman, C., Gotto, A. M., Jr., Morrisett, J. D., and Dahlen, G. H. (1982) Human Plasma Lipoprotein [a]. J. Biol. Chem. 258, 4582-4589.

7.Maranhao, R. C., Carvalho, P. O., Strunz, C. C., and Pileggi, F. (2014) Lipoprotein (a): Structure, Pathophysiology, and Clinical Implications. Arq Bras Cardiol. 103, 76-84.

Add to Cart
SKU PRICE (USD) UNIT QTY
400-45-0.1 $ 169.00 100 ug
400-45-1 $ 648.00 1 mg
400-45-10 Inquire 10 mg